Skip to main content

Advertisement

Log in

Treatment of Acute Optic Neuritis and Vision Complaints in Multiple Sclerosis

  • Multiple Sclerosis and Related Disorders (P Villoslada, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Multiple sclerosis is an autoimmune demyelinating disorder of the nervous system, in which almost all patients develop some degree of visual impairment during the disease. Optic neuritis is the most common and known visual affection and may be the initial clinical disease manifestation, but visual complaints can have a wide variety of presentations and some of them can lead to clinical confusion. Most symptoms are the result of acute injury and subsequent axonal loss in the afferent and efferent visual pathway, but others may be consequences of treatments. Currently, we can tell the functional and anatomical damage caused by multiple sclerosis by visual function test, measurement of eye movements, electrophysiological testing, optical coherence tomography, and magnetic resonance imaging. The purpose of this review is to describe the afferent and efferent visual symptoms associated with multiple sclerosis or multiple sclerosis treatment, and review the current and future therapeutic options available for them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol. 2002;13(6):375–80.

    Article  PubMed  Google Scholar 

  2. Martínez-Lapiscina E, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe A, Torres-Torres R, et al. The visual pathway as a model to understand brain damage in multiple sclerosis. Mult Scler. 2014.

  3. Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109(12):1673.

    Article  Google Scholar 

  4. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. Br J Ophthalmol. 2006;90(5):551.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. 2004;137(1):77–83.

    Article  PubMed  Google Scholar 

  6. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology. 2001;56:1514.

    Article  CAS  PubMed  Google Scholar 

  7. Roed HG, Langkilde A, Sellebjerg F, et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology. 2005;64:804.

    Article  CAS  PubMed  Google Scholar 

  8. Ruprecht K, Klinker E, Dintelmann T, et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology. 2004;63:1081.

    Article  CAS  PubMed  Google Scholar 

  9. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357:1576.

    Article  CAS  PubMed  Google Scholar 

  10. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463.

    Article  Google Scholar 

  11. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67:1242.

    Article  CAS  PubMed  Google Scholar 

  12. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503.

    Article  CAS  PubMed  Google Scholar 

  13. Heron G, Thompson KJ, Dutton GN. The symptomatic Pulfrich phenomenon can be successfully managed with a coloured lens in front of the good eye—a long- term follow-up study. Eye (Lond). 2007;21:1469–72.

    Article  CAS  Google Scholar 

  14. McGowan G, Ahmed TY, Heron G, Diaper C. The Pulfrich phenomenon; clumsiness and collisions which can be ameliorated. Pract Neurol. 2011;11(3):173–6.

    Article  PubMed  Google Scholar 

  15. Perkin GD, Rose FC. Uhthoff’s syndrome. Br J Ophthalmol. 1976;60(1):60–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Davis SL, Frohman TC, Crandall CG, et al. Modelling Uhthoff’s phenomenon in MS patients with internuclear ophthalmoparesis. Neurology. 2008;70(13 pt 2):1098Y1106.

    Google Scholar 

  17. Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. CONTINUUM Lifelong Learn Neurol. 2013;19(4):992–1006. The very latest and most comprehensive review of unusual symptoms and síndromes. in MS; essential reading.

    Article  Google Scholar 

  18. Keltner JL, Johnson CA, Spurr JO, et al. Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. 1993;111:231–4.

    Article  CAS  PubMed  Google Scholar 

  19. Plant GT, Kermode AG, Turano G, et al. Symptomatic retrochiasmal lesions in multiple sclerosis: clinical features, visual evoked potentials, and magnetic resonance imaging. Neurology. 1992;42:68–76.

    Article  CAS  PubMed  Google Scholar 

  20. Francis CE. Visual issues in multiple sclerosis. Phys Med Rehabil Clin N Am. 2013;24(4):687–702.

    Article  PubMed  Google Scholar 

  21. Zee DS. Internuclear ophthalmoplegia: pathophysiology and diagnosis. Baillieres Clin Neurol. 1992;1:455–70.

    CAS  PubMed  Google Scholar 

  22. Frohman EM, Frohman TC, O’Suilleabhain P, et al. Quantitative oculographic characterisation of internuclear ophthalmoparesis in multiple sclerosis: the versional dysconjugacy index Z score. J Neurol Neurosurg Psychiatry. 2002;73:51–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Serra A, Derwenskus J, Downey DL, et al. Role of eye movement examination and subjective visual vertical in clinical evaluation of multiple sclerosis. J Neurol. 2003;250:569–75.

    Article  PubMed  Google Scholar 

  24. Bolanos I, Lozano D, Cantu C. Internuclear ophthalmoplegia: causes and long-term follow-up in 65 patients. Acta Neurol Scand. 2004;110:161–5.

    Article  CAS  PubMed  Google Scholar 

  25. Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol. 2005;4(2):111–21.

    Article  PubMed  Google Scholar 

  26. Niestroy A, Rucker JC, Leigh RJ. Neuro-ophthalmologic aspects of multiple sclerosis: using eye movements as a clinical and experimental tool. Clin Ophthalmol. 2007;I(3):267–72.

    Google Scholar 

  27. Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin Ophthalmol. 2010;4:1409–22. A full update of the visual manifestations of multiple sclerosis and its management. Recommended reading.

    PubMed Central  PubMed  Google Scholar 

  28. Averbuch-Heller L, Tusa RJ, Fuhry L, et al. A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus. Ann Neurol. 1997;41:818–25.

    Article  CAS  PubMed  Google Scholar 

  29. Starck M, Albrecht H, Pollman W, et al. Drug therapy for acquired pendular nystagmus in multiple sclerosis. J Neurol. 1997;244:9–16.

    Article  CAS  PubMed  Google Scholar 

  30. Rucker JC. Current treatment of nystagmus. Curr Treat Options Neurol. 2005;7:69–77.

    Article  PubMed  Google Scholar 

  31. Leigh RJ, Tomsak RL. Drug treatments for eye movement disorders. J Neurol Neurosurg Psychiatry. 2003;74:1–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Buckley EG, Holgado S. Surgical treatment of upgaze palsy in Parinaud’s syndrome. J AAPOS. 2004;8:249–53.

    Article  PubMed  Google Scholar 

  33. Postert T, McMonagle U, Buttner T, et al. Paroxysmal convergence spasm in multiple sclerosis. Acta Neurol Scand. 1996;94(1):35–7.

    Article  CAS  PubMed  Google Scholar 

  34. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin. 1992;10(3):505–12.

    CAS  PubMed  Google Scholar 

  35. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin. Clin Rev Allerg Immunol. 2005;29(3):173–84.

    Article  CAS  Google Scholar 

  36. Oh KT, Boldt HC, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol. 1997;124(3):416–8.

    Article  CAS  PubMed  Google Scholar 

  37. Rubio JE, Charles S. Interferon-associated combined branch retinal artery and central retinal vein obstruction. Retina. 2003;23:546–8.

    Article  PubMed  Google Scholar 

  38. Tokai R, Ikeda T, Miyaura T, Sato K. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol. 2001;119:1077–9.

    CAS  PubMed  Google Scholar 

  39. Cohen JA, Rovaris M, Goodman AD, et al. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Neurology. 2007;68(12):939–44.

    Article  CAS  PubMed  Google Scholar 

  40. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290–7.

    Article  CAS  PubMed  Google Scholar 

  41. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.

    Article  CAS  PubMed  Google Scholar 

  42. Highlights of prescribing information: Gilenya (fingolimod) capsules. Novartis. 2012.

  43. Clifford DB, DeLuca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–46.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Ruben Torres-Torres and Bernardo F. Sanchez-Dalmau declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bernardo F. Sanchez-Dalmau MD.

Additional information

This article is part of the Topical Collection on Multiple Sclerosis and Related Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Torres-Torres, R., Sanchez-Dalmau, B.F. Treatment of Acute Optic Neuritis and Vision Complaints in Multiple Sclerosis. Curr Treat Options Neurol 17, 328 (2015). https://doi.org/10.1007/s11940-014-0328-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-014-0328-z

Keywords

Navigation